Barba-Romero M A, Barrot E, Bautista-Lorite J, Gutierrez-Rivas E, Illa I, Jimenez L M, Ley-Martos M, Lopez de Munain A, Pardo J, Pascual-Pascual S I, Perez-Lopez J, Solera J, Vilchez-Padilla J J
Department of Internal Medicine, Hospital General Universitario de Albacete, Spain.
Rev Neurol. 2012 Apr 16;54(8):497-507.
Before 2006, Pompe disease or glycogenosis storage disease type II was an incurable disease whose treatment was merely palliative. The development of a recombinant human alpha-glucosidase enzymatic replacement therapy has become the first specific treatment for this illness. The aim of this guide is to serve as reference for the management of the late-onset Pompe disease, the type of Pompe disease that develops after one year of age. In the guide a group of Spanish experts make specific recommendations about diagnosis, follow-up and treatment of this illness. With regard to diagnosis, the dried blood spots method is essential as the first step for the diagnosis of Pompe disease. The confirmation of the diagnosis of Pompe disease must be made by means of an study of enzymatic activity in isolated lymphocytes or a mutation analysis of the alpha-glucosidase gene. With regard to treatment with enzymatic replacement therapy, the experts say that is effective improving or stabilizating the motor function and the respiratory function and it must be introduced when the first symptoms attributable to Pompe disease appear.
2006年以前,庞贝氏病或糖原贮积病II型是一种无法治愈的疾病,其治疗仅仅是缓解症状。重组人α-葡萄糖苷酶酶替代疗法的开发已成为这种疾病的首个特异性治疗方法。本指南的目的是作为晚发型庞贝氏病管理的参考,晚发型庞贝氏病是指一岁以后发病的庞贝氏病类型。在该指南中,一组西班牙专家对这种疾病的诊断、随访和治疗提出了具体建议。关于诊断,干血斑法作为庞贝氏病诊断的第一步至关重要。庞贝氏病的诊断确认必须通过对分离淋巴细胞的酶活性研究或α-葡萄糖苷酶基因突变分析来进行。关于酶替代疗法的治疗,专家们表示,它在改善或稳定运动功能和呼吸功能方面是有效的,并且必须在出现庞贝氏病的首个症状时开始使用。